Celldex Therapeutics, Inc. (CLDX) stock
CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$28.04−0.55 (-1.92%)
Close on Nov 17, 2026Market cap $2.20BP/E –Yield –
Celldex Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Celldex Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$235.57M. For fiscal 2025 it was -$210.95M. The highest annual figure on record is -$29.87M in fiscal 2009.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$210.95M | – |
| FY2024 | Dec 31, 2024 | -$157.78M | – |
| FY2023 | Dec 31, 2023 | -$107.29M | – |
| FY2022 | Dec 31, 2022 | -$103.73M | – |
| FY2021 | Dec 31, 2021 | -$60.91M | – |
| FY2020 | Dec 31, 2020 | -$40.40M | – |
| FY2019 | Dec 31, 2019 | -$46.42M | – |
| FY2018 | Dec 31, 2018 | -$75.24M | – |
| FY2017 | Dec 31, 2017 | -$99.93M | – |
| FY2016 | Dec 31, 2016 | -$113.04M | – |
| FY2015 | Dec 31, 2015 | -$98.89M | – |
| FY2014 | Dec 31, 2014 | -$101.54M | – |
| FY2013 | Dec 31, 2013 | -$67.67M | – |
| FY2012 | Dec 31, 2012 | -$49.78M | – |
| FY2011 | Dec 31, 2011 | -$35.66M | – |
| FY2010 | Dec 31, 2010 | -$30.37M | – |
| FY2009 | Dec 31, 2009 | -$29.87M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$57.41M | – |
| Q1 FY2026 | Mar 31, 2026 | -$65.59M | – |
| Q4 FY2025 | Dec 31, 2025 | -$63.94M | – |
| Q3 FY2025 | Sep 30, 2025 | -$48.63M | – |
| Q2 FY2025 | Jun 30, 2025 | -$44.01M | – |
| Q1 FY2025 | Mar 31, 2025 | -$54.37M | – |
| Q4 FY2024 | Dec 31, 2024 | -$32.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.34M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$40.64M | – |
| Q4 FY2023 | Dec 31, 2023 | -$32.53M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.99M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.20M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.57M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.19M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$14.52M | – |
| Q3 FY2021 | Sep 30, 2021 | -$16.37M | – |
| Q2 FY2021 | Jun 30, 2021 | -$11.93M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.08M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.21M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.86M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.22M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.11M | – |
| Q4 FY2019 | Dec 31, 2019 | -$11.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.14M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.04M | – |
| Q1 FY2019 | Mar 31, 2019 | -$13.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.43M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.39M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.40M | – |
| Q1 FY2018 | Mar 31, 2018 | -$28.02M | – |
| Q4 FY2017 | Dec 31, 2017 | -$19.52M | – |
| Q3 FY2017 | Sep 30, 2017 | -$24.36M | – |
| Q2 FY2017 | Jun 30, 2017 | -$20.79M | – |
| Q1 FY2017 | Mar 31, 2017 | -$35.26M | – |
| Q4 FY2016 | Dec 31, 2016 | -$20.35M | – |
| Q3 FY2016 | Sep 30, 2016 | -$23.96M | – |
See a number that looks wrong?